OMER
Omeros Corporation
$16.57
-1.72%
2026-10-23
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Key Fundamentals
P/E Ratio
12.17
Forward P/E
16.33
EPS (TTM)
$1.65
Profit Margin
324.9%
Price/Book
-28.20
Beta
2.60
Market Cap
$1.45B
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$21.24
60D Low
$11.37
Avg Volume
1.7M
Latest Close
$16.57
Get breakout alerts for OMER
Sign up for Breakout Scanner to receive daily notifications when OMER triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Omeros Corporation (OMER) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors OMER daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. OMER operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.